[go: up one dir, main page]

MX2018006195A - Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk. - Google Patents

Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk.

Info

Publication number
MX2018006195A
MX2018006195A MX2018006195A MX2018006195A MX2018006195A MX 2018006195 A MX2018006195 A MX 2018006195A MX 2018006195 A MX2018006195 A MX 2018006195A MX 2018006195 A MX2018006195 A MX 2018006195A MX 2018006195 A MX2018006195 A MX 2018006195A
Authority
MX
Mexico
Prior art keywords
ntrk
compounds
compositions useful
disorders related
treating disorders
Prior art date
Application number
MX2018006195A
Other languages
English (en)
Inventor
Jr Bifulco Neil
L Kim Joseph
V Miduturu Chandrasekhar
Mark Wenglowsky Steven
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of MX2018006195A publication Critical patent/MX2018006195A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con inhibidores de NTRK que comprenden una estructura pirazolo[1,5-4]pirimidin-3-carbonitrilo. Son activos contra NTRK de tipo salvaje y sus mutaciones resistentes.
MX2018006195A 2015-11-19 2016-11-18 Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk. MX2018006195A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562257476P 2015-11-19 2015-11-19
PCT/US2016/062731 WO2017087778A1 (en) 2015-11-19 2016-11-18 Compounds and compositions useful for treating disorders related to ntrk

Publications (1)

Publication Number Publication Date
MX2018006195A true MX2018006195A (es) 2018-09-05

Family

ID=57517997

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006195A MX2018006195A (es) 2015-11-19 2016-11-18 Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk.

Country Status (18)

Country Link
US (2) US10370379B2 (es)
EP (1) EP3377497A1 (es)
JP (1) JP2019500328A (es)
KR (1) KR20180081790A (es)
CN (1) CN108431008A (es)
AR (1) AR106756A1 (es)
AU (1) AU2016355196A1 (es)
BR (1) BR112018010024A8 (es)
CA (1) CA3005741A1 (es)
HK (1) HK1259453A1 (es)
IL (1) IL259164A (es)
MX (1) MX2018006195A (es)
PH (1) PH12018501065A1 (es)
RU (1) RU2018122089A (es)
SG (2) SG11201803920TA (es)
TW (1) TWI733713B (es)
WO (1) WO2017087778A1 (es)
ZA (1) ZA201803530B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2916220T3 (es) 2012-07-11 2022-06-29 Blueprint Medicines Corp Inhibidores del receptor de factor de crecimiento de fibroblasto
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
SG11201602937UA (en) 2013-10-17 2016-05-30 Blueprint Medicines Corp Compositions useful for treating disorders related to kit
SMT202200292T1 (it) 2013-10-25 2022-09-14 Blueprint Medicines Corp Inibitori del recettore del fattore di crescita dei fibroblasti
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
MX2018001032A (es) 2015-07-24 2018-11-09 Blueprint Medicines Corp Compuestos utiles para el tratamiento de trastornos relacionados con kit y pdgfr.
WO2017035354A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
JP2019500328A (ja) 2015-11-19 2019-01-10 ブループリント メディシンズ コーポレイション Ｎｔｒｋに関連する障害の治療のために有用な化合物及び組成物
WO2017161269A1 (en) 2016-03-17 2017-09-21 Blueprint Medicines Corporation Inhibitors of ret receptor tyrosine kinases
CA3020870C (en) 2016-04-15 2024-04-30 Blueprint Medicines Corporation Inhibitors of activin receptor-like kinase
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
JP7278273B2 (ja) 2017-10-18 2023-05-19 ブループリント メディシンズ コーポレイション アクチビン受容体様キナーゼの阻害剤としての置換ピロロピリジン
ES2970041T3 (es) 2018-04-03 2024-05-24 Blueprint Medicines Corp Inhibidor de RET para su uso en el tratamiento del cáncer que tiene una alteración de RET
MA54092A (fr) 2018-10-30 2021-09-08 Kronos Bio Inc Composés, compositions et procédés de modulation de l'activité de cdk9
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
RS64881B1 (sr) 2019-04-12 2023-12-29 Blueprint Medicines Corp Kristalini oblici (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amin i načini pripreme
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
AU2020402942B2 (en) * 2019-12-13 2023-05-11 Scinnohub Pharmaceutical Co., Ltd Fluorine-containing heterocyclic derivatives with macrocyclic structure and use thereof
CN112979654B (zh) * 2019-12-16 2024-03-19 赛诺哈勃药业（成都）有限公司 杂芳基稠环化合物、其制备方法及应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
BR112022024382A2 (pt) 2020-05-29 2023-05-02 Blueprint Medicines Corp Formas sólidas de pralsetinibe

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5251911A (en) 1992-12-09 1993-10-12 Blake Carlton E Safety construction for passenger vehicle
EP0929553B1 (en) 1996-10-02 2005-03-16 Novartis AG Pyrimidine derivatives and processes for the preparation thereof
PL224879B1 (pl) * 2002-09-04 2017-02-28 Pharmacopeia Drug Discovery Inc Pirazolo [1,5-a] pirymidynowy związek, jego zastosowanie do wytwarzania leku oraz zawierająca go farmaceutyczna kompozycja
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
CN102924458B (zh) 2004-04-02 2014-11-05 Osi制药有限责任公司 6,6-双环取代的杂双环蛋白激酶抑制剂
CA2563699C (en) 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
WO2009032703A1 (en) 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
ES2900243T3 (es) 2008-10-22 2022-03-16 Array Biopharma Inc Compuestos de pirazolo[1,5-a]pirimidina sustituidos como inhibidores de trk quinasa
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2566866A1 (en) 2010-05-05 2013-03-13 Vertex Pharmaceuticals Incorporated 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
CN102241678B (zh) * 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
ES2916220T3 (es) 2012-07-11 2022-06-29 Blueprint Medicines Corp Inhibidores del receptor de factor de crecimiento de fibroblasto
WO2014036387A2 (en) 2012-08-31 2014-03-06 The Regents Of The University Of Colorado Methods for diagnosis and treatment of cancer
JP6457942B2 (ja) * 2012-10-05 2019-01-23 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ−８阻害剤
HK1214830A1 (zh) * 2012-11-05 2016-08-05 Foundation Medicine, Inc. 新型ntrk1融合分子及其应用
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
WO2014118226A1 (en) 2013-02-01 2014-08-07 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyrimidinylamino-indazoles
CN103965199B (zh) 2013-02-02 2017-07-07 广东东阳光药业有限公司 一种芳杂环化合物、包含它的药物组合物及其用途
RU2672910C9 (ru) * 2013-02-21 2019-06-04 Калитор Сайенсез, ЛЛС Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы
MX2015011898A (es) * 2013-03-13 2016-05-05 Genentech Inc Compuestos de pirazolo y usos de los mismos.
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
GB2515785A (en) 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
SG11201602937UA (en) 2013-10-17 2016-05-30 Blueprint Medicines Corp Compositions useful for treating disorders related to kit
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
SMT202200292T1 (it) 2013-10-25 2022-09-14 Blueprint Medicines Corp Inibitori del recettore del fattore di crescita dei fibroblasti
WO2015108328A1 (ko) * 2014-01-14 2015-07-23 주식회사 엘지생명과학 대장암 마커로서의 신규 ntrk1 융합유전자 및 이의 용도
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
WO2015157093A1 (en) * 2014-04-08 2015-10-15 Rigel Pharmaceuticals, Inc. 2,3-disubstituted pyridine compounds as tgf-beta inhibitors and methods of use
WO2016022569A1 (en) 2014-08-04 2016-02-11 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
KR20240055170A (ko) 2014-12-15 2024-04-26 주식회사 씨엠지제약 융합된 고리 헤테로아릴 화합물 및 trk 억제제로서의 이들의 용도
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
JP6800158B2 (ja) * 2015-02-20 2020-12-16 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ−８阻害剤
MX2018001032A (es) 2015-07-24 2018-11-09 Blueprint Medicines Corp Compuestos utiles para el tratamiento de trastornos relacionados con kit y pdgfr.
WO2017035354A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
JP2019500328A (ja) 2015-11-19 2019-01-10 ブループリント メディシンズ コーポレイション Ｎｔｒｋに関連する障害の治療のために有用な化合物及び組成物
WO2017161269A1 (en) 2016-03-17 2017-09-21 Blueprint Medicines Corporation Inhibitors of ret receptor tyrosine kinases
CA3020870C (en) 2016-04-15 2024-04-30 Blueprint Medicines Corporation Inhibitors of activin receptor-like kinase
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
WO2018049233A1 (en) 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
CN107844168B (zh) 2017-11-23 2020-12-01 英业达科技有限公司 主板组件及其卡扣装置

Also Published As

Publication number Publication date
BR112018010024A2 (pt) 2018-11-21
US10370379B2 (en) 2019-08-06
US20170145018A1 (en) 2017-05-25
RU2018122089A (ru) 2019-12-25
TW201720826A (zh) 2017-06-16
AU2016355196A1 (en) 2018-06-21
EP3377497A1 (en) 2018-09-26
CA3005741A1 (en) 2017-05-26
JP2019500328A (ja) 2019-01-10
AR106756A1 (es) 2018-02-14
TWI733713B (zh) 2021-07-21
BR112018010024A8 (pt) 2019-02-26
HK1259453A1 (zh) 2019-11-29
SG10201912607SA (en) 2020-02-27
US11059827B2 (en) 2021-07-13
PH12018501065A1 (en) 2019-01-28
IL259164A (en) 2018-06-28
SG11201803920TA (en) 2018-06-28
WO2017087778A1 (en) 2017-05-26
US20190382410A1 (en) 2019-12-19
RU2018122089A3 (es) 2019-12-30
ZA201803530B (en) 2021-08-25
CN108431008A (zh) 2018-08-21
KR20180081790A (ko) 2018-07-17

Similar Documents

Publication Publication Date Title
PH12018501065A1 (en) Compounds and compositions useful for treating disorders related to ntrk
ZA202401324B (en) Tyrosine kinase inhibitors
MX2025003987A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos
PH12018500397A1 (en) Compounds and compositions useful for treating disorders related to ntrk
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
MY194262A (en) Inhibitors of ret
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
MX2019001125A (es) Inhibidores de cinasa macrociclica.
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
PH12017501921A1 (en) Novel compounds
PH12017502050B1 (en) Naphthyridine compounds as jak kinase inhibitors
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
UA117830C2 (uk) Похідні біпіразолу як інгібітори jak
IN2014DN09134A (es)
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
MY189912A (en) Substituted xanthines and methods of use thereof
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2020005866A (es) Derivado de pirrolo(pirazolo)pirimidina como inhibidor de lrrk2.
WO2016073771A3 (en) Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors
SG10201805890QA (en) Compositions and methods for treatment of abnormal cell growth
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors
WO2013155465A8 (en) Substituted xanthine derivatives
MX2017014752A (es) Nuevos etinos de amidoheteroaril aroil hidrazida.